Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ESMO Breast 2022 and Esmo Breast 2022 View overview page

0:31
Exciting developments in ADCs for BC presented at ESMO Breast 2022
Rupert Bartsch • 5 May 2022
1:23
Exploring myeloid cells to reverse the hormone-mediated microenvironemnt of luminal breast cancer
Céline Blaye • 4 May 2022
0:27
Immunotherapy insights from ESMO Breast 2022
Céline Blaye • 4 May 2022
1:27
PRADA: evaluating radiotherapy before deep inferior flap reconstruction
Philip Poortmans • 3 May 2022
1:55
A new regimen of hypofractionated postoperative radiation therapy for breast cancer
Philip Poortmans • 3 May 2022
0:56
The significance of the annual ESMO Breast Cancer meeting
Sung-Bae Kim • 4 May 2022
1:03
Key lectures from ESMO Breast Cancer 2022
Sung-Bae Kim • 4 May 2022
1:21
The use of the Ki-67 in deciding which patients with HR+ breast cancer can safely avoid chemotherapy
Sung-Bae Kim • 4 May 2022
1:56
Optimizing adjuvant treatment in HR+/HER2- early breast cancer
Sung-Bae Kim • 5 May 2022
0:55
The clinical impact of gene expression assays on early luminal breast cancer
Nadia Harbeck • 4 May 2022
1:47
Can we decrease chemotherapy in LN+ premenopausal women based on genomic tests?
Nadia Harbeck • 4 May 2022
2:46
ELEANOR: observing real-life extended adjuvant therapy with neratinib and concurrent use of CONKADO
Nadia Harbeck • 4 May 2022
2:10
monarchE: adjuvant abemaciclib + endocrine therapy in patients with HR+, HER2- high-risk eBC
Nadia Harbeck • 4 May 2022
2:24
Evaluating the requirement for chemotherapy in patients with HR+ BC
Nadia Harbeck • 4 May 2022
1:59
ADAPT: de-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel in HR-/HER2+ eBC
Nadia Harbeck • 4 May 2022
1:18
The advantage of ADCs for the treatment of brain metastases
Rupert Bartsch • 5 May 2022
The content of VJOncology is intended for healthcare professionals